艾拉司群的专利技术分析

打开文本图片集

中图分类号：R979.1 文献标志码：A 文章编号：1003-5168（2025）07-0132-06

DOI：10.19968/j.cnki.hnkj.1003-5168.2025.07.026

Abstract： [Purposes] Based on patent information，this study aims to analyze the development history of Elacestrant，the world's first orally available selective estrogen receptor degrader （SERD）approved for market，assisting researchers in understanding the drug's development process，trends，and intellectual property protection in China.It also provides suggestions on technological development and intellectual property strategy for domestic pharmaceutical companies.[Methods] Patent literature related to Elacestrant was searched in the Himmpat and STN databases.After merging family patents，deduplication，and manual indexing to remove noise，48 valid patent documents were obtained.The analysis was conducted from the perspectives of pharmaceutical use，crystal forms， preparation methods，and combination therapies.[Findings] The original compound patent of Elacestrant，as the basic patent， was not applied for protection in China.The compound crystal forms，pharmaceutical uses，and combination therapies of Elacestrant are the focus of Radius Health's patent layout in China.[Conclusions] Radius Health has actively implemented patent layout in China from the perspectives of compound crystal forms，pharmaceutical uses，and combination therapies，achieving efective results.In contrast， domestic innovators mainly focus on the synthesis methods of Elacestrant and its important intermediates，with relatively less research on new pharmaceutical uses，drug formulations，and combination therapies of Elacestrant. Keywords：Elacestrant; oral SERD; breast cancer; patent analysis

0 引言

根据美国癌症协会最新发布数据，乳腺癌是美国女性癌症死亡的第2大原因，仅次于肺癌；我国国家癌症中心在期刊JournaloftheNationalCancerCenter最新发布的数据显示，在中国女性前10位恶性肿瘤死亡率排行中，乳腺癌排名第 。（剩余8810字）